결핵 진단 시장은 2031년까지 35억 6,000만 달러에 달할 것으로 예상되며, 2024-2031년간 5.0%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 철저한 2차 및 1차 조사, 시장 시나리오에 대한 심층 분석에 이어 주요 시장 성장 촉진요인, 저해요인, 과제, 기회 및 동향에 대한 논의가 이어집니다.
중저소득 국가에서 결핵 유병률 증가, 약제 내성 균주의 출현, 결핵 진단 및 치료에 대한 긍정적인 접근이 이 시장의 성장을 주도하고 있습니다. 또한, 결핵에 대한 인식을 높이기 위한 정부 및 조직의 노력은 결핵 진단 시장에서 사업을 운영하는 기업에게 성장 기회를 제공할 것으로 예상됩니다.
(주 : 주요 5개사의 SWOT 분석을 게재 예정)
Tuberculosis Diagnostics Market Size, Share, Forecast, & Trends Analysis by Test Type (Mantoux, IGRA, Radiography [X-ray, CT] Molecular [NAAT, WGS, Rapid] Culture, Sputum Smear), End User (Hospital, Diagnostic Lab), Infection Stage - Global Forecast to 2031
The tuberculosis diagnostics market is expected to reach $3.56 Billion by 2031, at a CAGR of 5.0% from 2024 to 2031. Following thorough secondary and primary research and in-depth analysis of the market scenario, the report discusses key industry drivers, restraints, challenges, opportunities, and trends
The growth of this market is driven by the rising prevalence of tuberculosis (TB) in low-and middle-income countries, the emergence of drug-resistant strains, and favorable initiatives for TB diagnosis and treatment. Moreover, initiatives by governments and organizations to raise awareness about tuberculosis are expected to generate growth opportunities for the players operating in the tuberculosis diagnostics market.
Based on test type, the market is segmented into skin test/Mantoux, radiographic tests, molecular tests, sputum smear microscopy, culture & drug resistance tests, and other test types. The molecular tests segment is projected to register the highest growth rate of 5.8% during the forecast period of 2024-2031. This segment's growth is driven by the high efficiency & accuracy of molecular tests, technological advancements in molecular diagnostic technology, increasing availability of molecular tests for TB, and initiatives by market players to introduce rapid molecular diagnostic tests for TB & drug resistance. Moreover, new guidelines by public organizations such as the WHO regarding molecular TB tests further drive the segment's growth. For instance, in March 2024, the WHO published recommendations on the use of a new class of diagnostic technologies: targeted next-generation sequencing (NGS) tests for the diagnosis of drug-resistant tuberculosis (TB).
Based on infection stage, the tuberculosis diagnostics market is segmented into active and latent. The active segment is expected to register the highest CAGR during the forecast period of 2024-2031. This growth can be attributed to the increasing prevalence of tuberculosis in low- and middle-income countries, aims and goals set by governments and public organizations to manage the TB burden, and growing instances of TB outbreaks.
Based on end user, the tuberculosis diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users. The diagnostic laboratories segment is expected to register the highest CAGR during the forecast period. This growth is driven by the increasing adoption of advanced technologies for TB diagnosis, including next-generation sequencing. Furthermore, diagnostic laboratories are more capable of investing in such technologies compared to clinics and small to medium-sized hospitals. Additionally, government and organizational initiatives aimed at raising awareness about tuberculosis further contribute to the segment's growth.
An in-depth analysis of the geographical scenario of the tuberculosis diagnostics market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 34.1% of the global tuberculosis diagnostics market, followed by Europe and Asia-Pacific.
However, the market in Asia-Pacific is projected to register the highest CAGR during the forecast period. Within Asia-Pacific, India and China are expected to present significant growth opportunities for players in the tuberculosis diagnostic market due to their large populations, high incidence of tuberculosis cases, and rising investments in healthcare. Additionally, the strong economic growth in both countries enables substantial investments in healthcare infrastructure and advancing tuberculosis testing technologies.
Key companies operating in the tuberculosis diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN GmbH (Germany), Hologic, Inc. (U.S.), bioMerieux SA (France), Danaher Corporation (U.S.), Oxford Immunotec Ltd. (U.K.), Hain Lifescience GmbH (Germany), Creative Diagnostics (U.S.).
Tuberculosis Diagnostics Market Assessment-by Test Type
(Note: Other Test Types include Urine Test, Breath Test, Cytokine Detection Assay, Cerebrospinal Fluid Test)
Tuberculosis Diagnostics Market Assessment-by Infection Stage
Tuberculosis Diagnostics Market Assessment-by End User
(Note: Other End Users include government, private organizations, and NGOs)
Tuberculosis Diagnostics Market Assessment-by Geography
(Note: SWOT analysis of the top 5 companies will be provided)